Go Pro
→ Musk says UBI is coming. I say it's already here. (From Freedom Financial) (Ad)tc pixel Free ABDX Stock Alerts

Abingdon Health (ABDX) Competitors

Abingdon Health logo
GBX 10.50 -0.25 (-2.33%)
As of 11:15 AM Eastern
Compare

ABDX vs. GDR, YGEN, GENI, AGL, and PRM

Should you buy Abingdon Health stock or one of its competitors? Abingdon Health's main competitors and comparable companies include genedrive (GDR), Yourgene Health (YGEN), GENinCode (GENI), ANGLE (AGL), and Proteome Sciences (PRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Abingdon Health compare to genedrive?

genedrive (LON:GDR) and Abingdon Health (LON:ABDX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

In the previous week, genedrive had 4 more articles in the media than Abingdon Health. MarketBeat recorded 4 mentions for genedrive and 0 mentions for Abingdon Health. genedrive's average media sentiment score of 1.05 beat Abingdon Health's score of 0.00 indicating that genedrive is being referred to more favorably in the media.

Company Overall Sentiment
genedrive Positive
Abingdon Health Neutral

0.1% of genedrive shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 29.0% of genedrive shares are owned by company insiders. Comparatively, 8.0% of Abingdon Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Abingdon Health has a net margin of -33.88% compared to genedrive's net margin of -500.75%. Abingdon Health's return on equity of -55.91% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
genedrive-500.75% -1,044.57% -74.09%
Abingdon Health -33.88%-55.91%-17.93%

Abingdon Health has higher revenue and earnings than genedrive. Abingdon Health is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
genedrive£929K24.54-£21.22M-£0.79N/A
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A

genedrive has a beta of 0.989, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.132, suggesting that its share price is 87% less volatile than the broader market.

Summary

genedrive beats Abingdon Health on 7 of the 13 factors compared between the two stocks.

How does Abingdon Health compare to Yourgene Health?

Abingdon Health (LON:ABDX) and Yourgene Health (LON:YGEN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 23.3% of Yourgene Health shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by insiders. Comparatively, 64.4% of Yourgene Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Abingdon Health has higher earnings, but lower revenue than Yourgene Health. Abingdon Health is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A

In the previous week, Abingdon Health's average media sentiment score of 0.00 equaled Yourgene Health'saverage media sentiment score.

Company Overall Sentiment
Abingdon Health Neutral
Yourgene Health Neutral

Abingdon Health has a beta of 0.132, indicating that its share price is 87% less volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Yourgene Health has a net margin of -27.55% compared to Abingdon Health's net margin of -33.88%. Yourgene Health's return on equity of -27.06% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
Yourgene Health -27.55%-27.06%-6.71%

Summary

Yourgene Health beats Abingdon Health on 8 of the 10 factors compared between the two stocks.

How does Abingdon Health compare to GENinCode?

GENinCode (LON:GENI) and Abingdon Health (LON:ABDX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Abingdon Health has higher revenue and earnings than GENinCode. Abingdon Health is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENinCode£3.08M2.34-£6.10M-£2.08N/A
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A

GENinCode has a beta of 0.557, meaning that its share price is 44% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.132, meaning that its share price is 87% less volatile than the broader market.

In the previous week, GENinCode had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for GENinCode and 0 mentions for Abingdon Health. GENinCode's average media sentiment score of 0.59 beat Abingdon Health's score of 0.00 indicating that GENinCode is being referred to more favorably in the media.

Company Overall Sentiment
GENinCode Positive
Abingdon Health Neutral

11.4% of GENinCode shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 8.4% of GENinCode shares are owned by insiders. Comparatively, 8.0% of Abingdon Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Abingdon Health has a net margin of -33.88% compared to GENinCode's net margin of -185.47%. Abingdon Health's return on equity of -55.91% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
GENinCode-185.47% -409.40% -63.99%
Abingdon Health -33.88%-55.91%-17.93%

Summary

Abingdon Health beats GENinCode on 7 of the 13 factors compared between the two stocks.

How does Abingdon Health compare to ANGLE?

Abingdon Health (LON:ABDX) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

3.7% of Abingdon Health shares are held by institutional investors. Comparatively, 17.5% of ANGLE shares are held by institutional investors. 8.0% of Abingdon Health shares are held by company insiders. Comparatively, 2.7% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ANGLE had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Abingdon Health. ANGLE's average media sentiment score of 0.67 beat Abingdon Health's score of 0.00 indicating that ANGLE is being referred to more favorably in the news media.

Company Overall Sentiment
Abingdon Health Neutral
ANGLE Positive

Abingdon Health has higher revenue and earnings than ANGLE. Abingdon Health is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A
ANGLE£2.62M2.89-£21.76M-£4.80N/A

Abingdon Health has a net margin of -33.88% compared to ANGLE's net margin of -1,444.04%. Abingdon Health's return on equity of -55.91% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
ANGLE -1,444.04%-191.36%-29.89%

Abingdon Health has a beta of 0.132, meaning that its stock price is 87% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

Summary

Abingdon Health beats ANGLE on 7 of the 13 factors compared between the two stocks.

How does Abingdon Health compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and Abingdon Health (LON:ABDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Proteome Sciences has a beta of 0.148, indicating that its stock price is 85% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.132, indicating that its stock price is 87% less volatile than the broader market.

In the previous week, Proteome Sciences had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for Proteome Sciences and 0 mentions for Abingdon Health. Proteome Sciences' average media sentiment score of 0.00 equaled Abingdon Health'saverage media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
Abingdon Health Neutral

Abingdon Health has a net margin of -33.88% compared to Proteome Sciences' net margin of -81.50%. Proteome Sciences' return on equity of 33.80% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
Abingdon Health -33.88%-55.91%-17.93%

0.0% of Proteome Sciences shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 36.7% of Proteome Sciences shares are owned by insiders. Comparatively, 8.0% of Abingdon Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Abingdon Health has higher revenue and earnings than Proteome Sciences. Abingdon Health is trading at a lower price-to-earnings ratio than Proteome Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.45-£4.08M-£1.04N/A
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A

Summary

Abingdon Health beats Proteome Sciences on 7 of the 12 factors compared between the two stocks.

Get Abingdon Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABDX vs. The Competition

Export
MetricAbingdon HealthLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£26.36M£10.03B£7.28B£2.91B
Dividend YieldN/A1.46%2.53%6.18%
P/E Ratio-12.9665.01272.42367.42
Price / Sales2.75112.07623.3983,891.79
Price / Cash2.2527.0477.3927.89
Price / Book14.4335.9812.856.75
Net Income-£796.37K£56.67B£3.47B£5.89B
7 Day Performance-1.99%-0.83%1.24%5.57%
1 Month Performance-2.51%4.54%5.81%2.30%
1 Year Performance90.74%26.48%25.75%21.81%

Abingdon Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABDX
Abingdon Health
N/AGBX 10.50
-2.3%		N/A+89.3%£26.36M£9.57MN/A84
GDR
genedrive
N/AGBX 1.40
+5.7%		N/A+195.9%£22.48M£929KN/A43
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
GENI
GENinCode
N/AGBX 1.01
+6.0%		N/A-29.9%£7.58M£3.08MN/A2,300
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-68.7%£7.58M£2.62MN/A650

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:ABDX) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
Trump’s “new Petrodollar” exposed
Trump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the en...
Porter & Company | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Man Who Called SpaceX Rise Says Elon’s NEW Project is Even Bigger
James Altucher called the rise of Nvidia, Apple, and SpaceX years before the crowd. Now he says he has uncover...
Paradigm Press | Sponsoredtc pixel
Half the market is standing on a trapdoor
Nearly half the value of the US stock market now sits in AI stocks - the most concentrated the market has been...
Behind the Markets | Sponsoredtc pixel
Wall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)
The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...
Weiss Ratings | Sponsoredtc pixel
This Overlooked Fund Turns AI Stocks Into Weekly Income
A small fund pays investors weekly income from AI stocks that don't pay dividends on their own. Chief Incom...
Investors Alley | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel